The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches
Authors:
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (3) , 597-604
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences
This publication has 64 references indexed in Scilit:
- Autoimmunity associated with immunotherapy of cancerBlood, 2011
- Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)Journal of the American Academy of Dermatology, 2010
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-α receptorBlood, 2008
- A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoidesJournal of the American Academy of Dermatology, 2006
- Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institutionJournal of the American Academy of Dermatology, 1996
- Adverse Effects of Interferon on the Cardiovascular System in Patients with Chronic Hepatitis C.Japanese Heart Journal, 1996
- Interferon alfa-2a in the treatment of cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1989
- Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal PhotochemotherapyNew England Journal of Medicine, 1987